MC
ANIP icon

Menta Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Menta Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-16,750
Closed -$935K – 807
2016
Q2 		$935K Buy
16,750
+4,703
+39% +$229K 0.13% 267
2016
Q1 		$406K Buy
+12,047
New +$409K 0.06% 585

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Menta Capital's ANIP Position: Q3 2016 in Review

Menta Capital sold out of ANI Pharmaceuticals (ANIP) in Q3 2016, closing a stake of 16,750 shares — an estimated $935K sold.

Menta Capital first reported a position in ANIP in Q1 2016 and held it in 2 quarters. The position peaked at $935K in Q2 2016. 171 funds tracked by Wall St. Rank hold ANIP as of Q3 2016.

  • Menta Capital reported no remaining ANI Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Menta Capital sold 16,750 ANI Pharmaceuticals shares in Q3 2016, an estimated $935K.
  • Menta Capital first reported a position in ANI Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Menta Capital's ANI Pharmaceuticals position peaked at $935K in Q2 2016.
  • 171 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2016.

Based on Menta Capital's 13F filing for Q3 2016, filed 14 Nov 2016.